Therapeutic approaches for T790M mutation positive non-small-cell lung cancer

被引：25
|
作者：
Attili, Ilaria [1 ]
Karachaliou, Niki [2 ,3 ]
Conte, PierFranco [1 ]
Bonanno, Laura [4 ]
Rosell, Rafael [3 ,5 ,6 ,7 ]
机构：
[1] Univ Padua, Dept Surg Oncol & Gastroenterol Sci, Padua, Italy
[2] Univ Hosp Sagrat Cor, Inst Oncol Dr Rosell IOR, Barcelona, Spain
[3] Quiron Dexeus Univ Inst, Coyote Res Grp, Pangaea Oncol, Mol Biol Lab, Barcelona, Spain
[4] IRCCS, Ist Oncol Veneto, Med Oncol 2, Padua, Italy
[5] Inst Invest Ciencies Germans Trias & Pujol, Badalona, Spain
[6] Quiron Dexeus Univ Inst, Inst Oncol Dr Rosell IOR, Barcelona, Spain
[7] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2018年 / 18卷 / 10期
关键词：
EGFR; lung cancer; osimertinib; TKI resistance; liquid biopsy; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; 3RD-GENERATION EGFR INHIBITORS; ACQUIRED-RESISTANCE; MET AMPLIFICATION; OPEN-LABEL; OSIMERTINIB AZD9291; 1ST-LINE TREATMENT; TKI RESISTANCE; PHASE-III;
D O I：
10.1080/14737140.2018.1508347
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Introduction: Epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) is a subset of lung cancer with demonstrated response to targeted therapies. However, resistance to the first targeted approach usually occurs within the first year, and it is associated in 50-60% of cases to the T790M resistance mutation.Areas covered: The review provides an overview on the significance of the presence of the T790M mutation, its detection, treatment options and subsequent mechanisms of resistance.Expert commentary: Osimertinib is the current treatment option for T790M mutation positive NSCLC after progression to first or second-generation EGFR TKIs, with activity also on brain metastasis. However, the scenario is in continuous evolution and results from clinical trials are awaited in first-line setting and in combination strategies.
引用
收藏
页码：1021 / 1030
页数：10
相关论文
共 50 条
  • [31] REBIOPSY OF NON-SMALL-CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI: COMPARISON BETWEEN T790M MUTATION-POSITIVE AND -NEGATIVE POPULATIONS
    Hata, A.
    Katakami, N.
    Yoshioka, H.
    Tanaka, K.
    Nishiyama, A.
    Nanjo, S.
    Kaji, R.
    Fujita, S.
    Monden, K.
    Matsumoto, T.
    Nagata, K.
    Otsuka, K.
    Tachikawa, R.
    Tomii, K.
    Iwasaku, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 117 - 117
  • [32] Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer
    Fujii, Akiko
    Harada, Taishi
    Iwama, Eiji
    Ota, Keiichi
    Furuyama, Kazuto
    Ijichi, Kayo
    Okamoto, Tatsuro
    Okamoto, Isamu
    Takayama, Koichi
    Nakanishi, Yoichi
    CANCER GENETICS, 2015, 208 (05) : 271 - 278
  • [33] ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)
    Zhou, Q.
    Zhang, H. -L.
    Jiang, L. -Y.
    Shi, Y. -K.
    Chen, Y.
    Yu, J. -M.
    Zhou, C. -C.
    He, Y.
    Hu, Y. -P.
    Liang, Z. -A.
    Pan, Y. -Y.
    Zhuo, W. -L.
    Song, Y.
    Wu, G.
    Chen, G. -Y.
    Lu, Y.
    Zhang, C. -Y.
    Zhang, C. -Y.
    Zhang, Y. -P.
    Chen, Y.
    Lu, S.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S429 - S430
  • [34] Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance
    Wang, Ying
    Liu, Qiuyun
    Chen, Haojie
    You, Jun
    Peng, Bin
    Cao, Fanfan
    Zhang, Xue
    Chen, Qing
    Uzan, Georges
    Xu, Limin
    Zhang, Denghai
    ANTI-CANCER DRUGS, 2018, 29 (08) : 748 - 755
  • [35] Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer
    Koo, Hyun Jung
    Kim, Mi Young
    Park, Sojung
    Lee, Han Na
    Kim, Hwa Jung
    Lee, Jae Cheol
    Kim, Sang-We
    Lee, Dae Ho
    Choi, Chang-Min
    RADIOLOGY, 2018, 289 (01) : 227 - 237
  • [36] Improving the use of sequential versus upfront osimertinib in EGFR-positive non-small-cell lung cancer: An audit of the T790M biopsy
    Yan, Kelvin
    Hota, Shweta
    Bakhtiar, Arizah
    Evans, Joanne
    CLINICAL ONCOLOGY, 2022, 34 : E4 - E4
  • [37] ANTITUMOR ACTIVITY OF BEVACIZUMAB COMBINED WITH ERLOTINIB IN T790M RESISTANCE MUTATION POSITIVE NON-SMALL CELL LUNG CANCER XENOGRAFT MODELS
    Furugaki, K.
    Yamamoto, K.
    Moriya, Y.
    Suda, K.
    Mizuuchi, H.
    Mitsudomi, T.
    Harada, N.
    ANNALS OF ONCOLOGY, 2014, 25
  • [38] High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer
    Ariyasu, Ryo
    Nishikawa, Shingo
    Uchibori, Ken
    Oh-hara, Tomoko
    Yoshizawa, Takahiro
    Dotsu, Yosuke
    Koyama, Junji
    Saiki, Masafumi
    Sonoda, Tomoaki
    Kitazono, Satoru
    Yanagitani, Noriko
    Horiike, Atsushi
    Inase, Naohiko
    Kasahara, Kazuo
    Nishio, Makoto
    Katayama, Ryohei
    LUNG CANCER, 2018, 117 : 1 - 6
  • [39] Clinical utility of repeated rebiopsy for EGFR T790M mutation detection in non-small cell lung cancer
    Lee, Eun Hye
    Kwak, Se Hyun
    Kim, Kyeong Yeon
    Kim, Chi Young
    Lee, Sang Hoon
    Heo, Seok-Jae
    Chang, Yoon Soo
    Kim, Eun Young
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [40] A Durable Response to Osimertinib in an Elderly Patient With EGFR T790M Positive Metastatic Non-Small-Cell Lung Cancer After Progression on Erlotinib
    Tariq, Zeeshan
    Blyly, Mckenna
    AMERICAN JOURNAL OF THERAPEUTICS, 2023, 30 (05) : E463 - E465
12345